Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI
201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus
(HCV) genotype 1 infection. Combination therapy of BI 201335 (Faldaprevir) with pegylated
interferon α-2a (PegIFN) and ribavirin (RBV), with or without a 3-day lead-in, was assessed
in treatment-naïve (TN) and treatment experienced (TE) patients.